

Case Number:	CM15-0077864		
Date Assigned:	04/29/2015	Date of Injury:	06/29/2012
Decision Date:	06/29/2015	UR Denial Date:	03/31/2015
Priority:	Standard	Application Received:	04/23/2015

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/Service. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

The Expert Reviewer has the following credentials:

State(s) of Licensure: New York

Certification(s)/Specialty: Anesthesiology

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

The injured worker (IW) is a 59-year-old male who sustained an industrial injury on 06/29/2012. Diagnoses include cervical radiculopathy, cervical disc protrusion, left shoulder osteoarthritis, left shoulder adhesive capsulitis, status post left shoulder surgery and left elbow sprain/strain. Treatment to date has included medications, shoulder manipulation and physical therapy. Diagnostics included MRIs and x-rays. According to the progress notes dated 2/23/15, the IW reported constant neck pain rated 3/10 radiating to the bilateral upper extremities with numbness and tingling, constant left shoulder pain, rated 7/10 and constant left elbow pain rated 4/10. A request was made for Genecin capsules, #90, Capsaicin 0.025 Flurbi (NAP) cream LA 180gms #1, Terocin 120 ml, #1 and Somnicin capsules, #30 for treatment of pain, inflammation and to promote rest and relaxation.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Somnicin #30: Upheld

Claims Administrator guideline: The Claims Administrator did not cite any medical evidence for its decision.

MAXIMUS guideline: The Expert Reviewer did not base their decision on the MTUS. Decision based on Non-MTUS Citation Official Disability Guidelines (ODG) Insomnia treatment.

Decision rationale: According to the ODG, melatonin is recommended for insomnia treatment. Melatonin also has an analgesic effect in patients with chronic pain. Somnicin contains melatonin, 5-HTP, L-tyrptopan, Vitamin B6 and magnesium. The documentation does not indicate that this patient has a sleep disturbance. Medical necessity for the requested item has not been established. The requested medication is not medically necessary.

Terocin 120 ml #1: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

Decision rationale: According to the California MTUS Guidelines, topical analgesics are primarily recommended for neuropathic pain when trials of antidepressants and anticonvulsants have failed. These agents are applied topically to painful areas with advantages that include lack of systemic side effects, absence of drug interactions, and no need to titrate. Many agents are compounded as monotherapy or in combination for pain control including, for example, NSAIDs, opioids, capsaicin, local anesthetics or antidepressants. Any compounded product that contains at least one drug (or drug class) that is not recommended is not recommended. In this case, there is no documentation provided necessitating Terocin. This medication contains methyl salicylate, capsaicin, menthol, and lidocaine. MTUS states that capsaicin is recommended only as an option in patients who have not responded or are intolerant to other treatments. There is no documentation of intolerance to other previous oral medications. Medical necessity for the requested topical medication has not been established. The requested treatment is not medically necessary.

Capsaicin 0.025, Flurb (NAP) cream LA 180 gms #1: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics Page(s): 111-113.

Decision rationale: According to the California MTUS Guidelines, topical analgesics are primarily recommended for neuropathic pain when trials of antidepressants and anticonvulsants have failed. These agents are applied topically to painful areas with advantages that include lack of systemic side effects, absence of drug interactions, and no need to titrate. Many agents are compounded as monotherapy or in combination for pain control including, for example, NSAIDs, opioids, capsaicin, local anesthetics or antidepressants. Any compounded product that

contains at least one drug (or drug class) that is not recommended is not recommended. In this case, the medication contains flurbiprofen and, capsaicin. MTUS guidelines state that flurbiprofen is not recommended for topical application and capsaicin is recommended only as an option in patients who have not responded or are intolerant to other treatments. There is no documentation of intolerance to other previous oral medications. Medical necessity for the requested topical medication has not been established. The requested treatment is not medically necessary.

Genecin #90: Upheld

Claims Administrator guideline: The Claims Administrator did not cite any medical evidence for its decision.

MAXIMUS guideline: The Expert Reviewer did not base their decision on the MTUS. Decision based on Non-MTUS Citation Official Disability Guidelines (ODG) Genecin.

Decision rationale: According to the ODG, Genicin (glucosamine) is not recommended for the treatment of low back pain. Glucosamine is not significantly different from placebo for reducing pain-related disability or improving health-related quality of life in patients with chronic low back pain (LBP) and degenerative lumbar osteoarthritis, and it should not be recommended for patients with lower back pain. Glucosamine is a precursor molecule involved in building tendons, ligaments, and cartilage. It is hypothesized to restore cartilage and to have anti-inflammatory properties, and, despite conflicting data on its efficacy, has become widely used as a treatment for osteoarthritis. It has also become more widely used for LBP, including degenerative lumbar osteoarthritis. In this case, the patient has chronic neck and shoulder pain and there is no indication for the use of genicin in the treatment of these chronic pain conditions. Medical necessity for the requested medication has not been established. This medication is not medically necessary.